718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models

• Christopher Nirschl,
• Kristin Morris,
• Heather Brodkin,
• Daniel Hicklin,
• Nesreen Ismail,
• Andres Salmeron,
• Philipp Steiner,
• Zoe Steuert,
• Jenna Sullivan,
• William Winston,
• Cindy Seidel-Dugan

Affiliations

Christopher Nirschl

Aff1 grid.38142.3c000000041936754XBrigham and Women`s Hospital, Department of DermatologyHarvard Medical School Boston MA USA

Kristin Morris

1Werewolf Therapeutics, Cambridge, MA, United States

Heather Brodkin

1Werewolf Therapeutics, Cambridge, MA, United States

Daniel Hicklin

1Werewolf Therapeutics, Cambridge, MA, United States

Nesreen Ismail

1Werewolf Therapeutics, Cambridge, MA, United States

Andres Salmeron

1Werewolf Therapeutics, Cambridge, MA, United States

Philipp Steiner

1Werewolf Therapeutics, Cambridge, MA, United States

Zoe Steuert

1Werewolf Therapeutics, Cambridge, MA, United States

Jenna Sullivan

2Werewolftx.com, Cambridge, MA, United States

William Winston

1Werewolf Therapeutics, Cambridge, MA, United States

Cindy Seidel-Dugan

Werewolf Therapeutics, Cambridge, MA, United States